



Published in final edited form as:

Wiley Interdiscip Rev Membr Transp Signal. ; 2(6): . doi:10.1002/wmts.95.

## Solute Carrier Family SLC41, what do we really know about it?

**Andrea Fleig**<sup>1</sup>,

Laboratory of Cell and Molecular Signalling, Center for Biomedical Research at The Queen's Medical Center, Honolulu, HI USA

**Monika Schweigel-Röntgen**<sup>1</sup>, and

Institute for Nutritional Physiology "Oskar Kellner", Leibniz Institute for Farm Animal Biology, Dummerstorf, Germany

**Martin Kolisek**

Institute für Veterinär-Physiologie, Freie Universität Berlin, Oertzenweg 19b, 14163 Berlin, Germany; tel: +49-30-838-62598

Martin Kolisek: martink@zedat.fu-berlin.de

### Abstract

The 41<sup>st</sup> family of solute carriers (SLC41) comprises three members A1, A2 and A3, which are distantly homologous to bacterial Mg<sup>2+</sup> channel MgtE. SLC41A1 was recently characterized as being an Na<sup>+</sup>/Mg<sup>2+</sup> exchanger (NME; a predominant cellular Mg<sup>2+</sup> efflux system). Little is known about the exact function of SLC41A2 and SLC41A3, although, these proteins have also been linked to Mg<sup>2+</sup> transport in human (animal) cells. The molecular biology (including membrane topology, cellular localization, transcriptomics and proteomics) of SLC41A2 and SLC41A3 compared with SLC41A1 has only been poorly explored. Significantly more data with regard to function, functional regulation, involvement in cellular signalling, complex-forming ability, spectrum of binding partners and involvement in the pathophysiology of human diseases are available for SLC41A1. Three recent observations namely the identification of the null mutation, c.698G>T, in SLC41A1 underlying the nephronophthisis-like phenotype, the recognition of a putative link between SLC41A1 and Parkinson's disease, and the observation that nearly 55% of preeclamptic placental samples overexpress *SLC41A1*, marks the protein as a possible therapeutic target of these diseases. A potential role of the SLC41 family of Mg<sup>2+</sup> transporters in the pathophysiology of human diseases is further substantiated by the finding that SLC41A3 knockout mice develop abnormal locomotor coordination.

### Introduction

The importance of magnesium (Mg) for normal cellular, tissue, organ, and body physiology has been described in many original papers and reviews. However, the molecular entities responsible for Mg<sup>2+</sup>-transport in higher eukaryotes and their intracellular distribution have started to be identified only recently. During the last decade, several genes have been shown to encode for putative or confirmed Mg<sup>2+</sup> transport systems (homeostatic factors) in humans, mammals and other higher eukaryotes (Tab. 1). In view of the large spectrum of processes that involve Mg, this count is likely not final.

Correspondence to: Martin Kolisek, martink@zedat.fu-berlin.de.

<sup>1</sup>These authors contributed equally.

#### Contributions

AF, MSR & MK wrote the manuscript. All authors read and approved the manuscript.

An exciting journey aimed at identify genes encoding for  $Mg^{2+}$  transporter molecules was begun in 1976 with the pioneering work of Park and colleagues who identified *corA*, *corB* and *mgt* mutants affecting  $Mg^{2+}$ -transport in *E. coli* [1]. In 1986 the group around M. E. Maguire cloned a predominant bacterial  $Mg^{2+}$ -transport system *CorA* from *Salmonella typhimurium* [2]. Shortly afterwards this was followed by the cloning of  $Mg^{2+}$ -regulated *MgtA* and *MgtB* P-type ATPases (both from *S. typhimurium*) [3] and of *MgtE*, an  $Mg^{2+}$ -channel with limited phylogenetic distribution (cloned from *Prowidencia stuartii*) [4]. In 2003, Wabbaken and colleagues cloned a human homologue of *MgtE* named solute carrier family 41 member A1 (*SLC41A1*; in the following, only given as A1) [5]. Goytain and Quamme demonstrated that A1 and also *SLC41A2* and *SLC41A3* (both also distantly homologous with *MgtE*; both cloned from *Mus musculus*; in the following, only given as A2 and A3) from the same protein family were able to conduct the electrogenic transport of  $Mg^{2+}$  when heterologously expressed in *Xenopus laevis* oocytes [6, 7, 8]. The A1 or A2-dependent electrogenic transport of  $Mg^{2+}$  seen in *Xenopus* oocytes was not observed in mammalian or avian cellular systems transfected with human A1 or A2 [9, 10]. The molecular biology and physiology of A3 remains unexplored. In regards to A2, only limited knowledge to its exact function(s) and mode of operation is currently available. However, A1, despite initial thoughts that it might represent an ion channel mechanism, has now been shown to function as a  $Na^+/Mg^{2+}$  exchanger (NME), at least in human and mammalian cells [11]. The discovery of A1 being an NME has physically bridged a large pool of knowledge concerning the physiology and pathophysiology of  $Na^+/Mg^{2+}$  exchange (a mechanism known for three decades as being extant) with an opportunity to perform a molecular examination of NME suspected to be directly or indirectly involved in a plethora of ailments of mankind.

## Transcriptomics, Cellular Localization, Topology and Complex-Forming Abilities of *SLC41A1*, A2 and A3

Transcripts of the human genes *SLC41A1* (1q31-32), *SLC41A2* (12q23.3) and *SLC41A3* (3q21.2) have been identified in various organs and tissues. The A1 transcript is abundantly expressed in heart, in testis and also in the adrenal and thyroid glands, in prostate and in ovaries whereas lower levels have been detected in all other tested tissues. To date it has also been detected in all tested cell lines such as HEK-293, Tom-1, BV173, Reh, Jurkat and JVM-13 [5, 9, 11, Kolisek *et al.*, unpublished]. Therefore, we can assume that member A1 is ubiquitously expressed in human cells. Romanuik and colleagues [12] have identified A1-expression as being responsive to androgens. No information is available about the expression of human A2 and A3 across human tissues and organs in peer-reviewed bibliography. However, some information can be extracted from [www.proteinatlas.org](http://www.proteinatlas.org).

All three members of the SLC41 family (human A1, 513 aa, 56 kDa; human A2, 573 aa, 62.3 kDa; human A3, 500 aa, 54.6 kDa) were predicted and also experimentally confirmed by functional studies as being proteins integral to the cytoplasmic membrane (A1 and A2 in both human and mouse models, A3 only in the mouse model) [6, 7, 8, 9, 10, 11]. However, Sahni and Scharenberg in their recent review [13] advocate the targeting of A2 into membranes of intracellular compartments.

The membrane topology of A1 is controversial. Initially, the ten transmembrane helices (TM) “inside-in” model of A1 topology was predicted (Fig. 1A, Tab. 2) [5]. Results of the computer-predictions of A1 topology are summarized in table 2. The results of independent studies have lead to a consensus concerning the intracellular orientation of the N-terminus of member A1 [9, 11, 14]. However, data regarding the C-terminus orientation are contradictory. Based on their epitope-tagging studies, the group of Mandt [14] has proposed a model possessing eleven TM and a C-terminus oriented extracellularly (Fig. 1A). In

contrast, Sponder and colleagues [15], by utilizing the split-ubiquitin functional assay in yeast, demonstrate that “A1 C-terminally tagged with a *Cub-LexA-VP16* reporter cassette is targeted to cytoplasmic membrane and that the C-terminus is oriented such that it allows the reconstitution of functional ubiquitin and is, therefore, intracellular”. It conforms with the study of Nestler and colleagues [16], claiming that the bait vector pBT3-STE, carrying the *Cub-LexA-VP16* moiety fused to the C-terminus of A1, is suitable for split-ubiquitin yeast two hybrid assay (SU-YTH) with SLC41A1 serving as the bait (intracellular/intracytosolic orientation of the reporter moiety is the precondition for performing SU-YTH assay). Thus, the data of Sponder and colleagues [15] support the initially proposed ten TM “inside-in” model (Fig. 1A). Only further research, e.g. showing that A1 C-terminally tagged with *Cub-LexA-VP16* is functional, will shed more light on the exact organization of A1 topology.

The strongly preferred computer-predicted model of SLC41A2 topology (TMPred at [www.ch.embnet.org](http://www.ch.embnet.org)) possesses ten TM with both termini being oriented extracellularly. However, Sahni and colleagues have demonstrated experimentally that the N-terminus of A2 is oriented extracellularly and the C-terminus intracellularly when overexpressed in DT40 chicken cells and, therefore, they have proposed the eleven TM “outside-in” model of membrane topology of A2 (Fig. 1B) [10]. Considering the structure-function relationship determined for MgtE, Sahni and Scharenberg have recently concluded that, in their pilot study [10], A2 has most probably been mistargeted to the cytoplasmic membrane as a result of its overexpression. Their assumption that A2 is primarily functional in the membranes of the intracellular compartments must be further tested (Fig. 1B) [13]. The online-generated prediction of A3 topology is shown at figure 1C. The computer analyses do not reveal any specific targeting-(signal)-sequences, therefore, a more specific intracellular localization of A2 or A3 may not be assumed (<http://www.cbs.dtu.dk/services/SignalP/>).

Kolisek and colleagues have shown that A1 forms protein complexes with high molecular mass *in vivo* [9]. Moreover, they propose that these complexes have a hetero-oligomeric character [9]. Recently, Nestler and colleagues have utilized SU-YTH assay and matrix-assisted laser desorption ionization-time of flight mass spectrometry (MLDI-TOF-MS) and identified multiple binding partners of A1 [16]. The most prominent binding partners of A1 identified are 3-beta-hydroxysteroid- $\Delta(8),\Delta(7)$ -isomerase (emopamil-binding protein) and B-cell receptor associated-protein 31. Other binding partner candidates include: IER3IP1, PPIB, UPF0480 protein C15orf24, SPINT2, C14orf1/PEBP28, NIFIE14, YIPF6, KCP2, SLC31A2, SLC35B1, SLC39A13, CRACM1, MTCH2, ACCA1, UBB, ATX2L, HSP7C and TBB. These are mostly proteins integral to membranes constituting the endoplasmic reticulum (ER) and Golgi apparatus (GA) (Fig. 2A) and playing a role in proteoneogenesis, proper folding, maturation, secretion, anterograde transport, and the regulation of apoptosis (Fig. 2B). Interestingly, among the binding partners of A1 other members of the SLC superfamily involved in lysosomal  $\text{Cu}^{2+}$ -, GA  $\text{Zn}^{2+}$ - and ER sugar-transport have been identified. Nestler and colleagues therefore speculate that these proteins undergo similar modifications with regard to their maturation (posttranslational modification in ER and GA) as A1 [16].

So far, no information is available about the complex-forming abilities of A2 and A3.

Goytain and Quamme [6] have proposed N-glycosylation as a possible posttranslational modification of A1. The NetNGlyc 1.0 prediction machine (DTU) indeed recognizes four putative glycosylation sequons within the sequence of A1. Three of them are located within the N-terminal cytoplasmic domain, and only the fourth is located in the putative extracellular loop (aa<sub>463</sub> – aa<sub>483</sub>; TMPred at [ch.EMBnet.org](http://ch.EMBnet.org)). Therefore, the identification of a component of oligosaccharyltransferase (KCP2) among putative A1-binding partners further substantiates N-glycosylation as a possible posttranslational modification of A1 [16].

Several functional studies have demonstrated that phosphorylation mediated via cAMP-activated protein kinase A (PKA) [5,8] and PKC [9] plays a key role in the regulation of  $\text{Na}^+/\text{Mg}^{2+}$  exchange. Indeed, Kolisek and colleagues [11] have shown that phosphorylation mediated by cAMP-activated PKA is an important event for the activation of A1-mediated  $\text{Mg}^{2+}$  efflux ( $\text{Na}^+/\text{Mg}^{2+}$  exchange). The N-terminal flanking sequence of A1, which seems to be an important regulatory region [10, 11, 15], possesses, in addition to the predicted PKC-phosphorylation sites, multiple putative phosphorylation hotspots for p38MAPK, cdc2, GSK3, cdk5, DNAPK and CKII (NetPhos 1.0; [15]). Involvement of these protein kinases in the regulation of A1 function remains to be explored.

Moreover, ubiquitination seems to play a role in the regulation of A1 turnover. Computer prediction has revealed ubiquitination hotspots at positions 4, 8, 58, 92, 146 and 339 (<http://bdmpub.biocuckoo.org>). The role of ubiquitination in the turnover/degradation of A1 has been substantiated by MALDI-TOF-MS analysis combined with in-gel trypsin digestion, performed on Coomassie-stained protein bands resulting from the electro-separation of affinity-purified strep-A1 (performed under native conditions) and its potential binding partners [16]. Nestler and colleagues have demonstrate that a protein band with a molecular mass well exceeding 170 kDa comprises A1, ACCA1 and ubiquitin, therefore, indicating that A1, or ACCA1 or both are prone to ubiquitination [16].

### SLC41 family of $\text{Mg}^{2+}$ carriers

Experimental data in favour of two mechanisms have been presented in the literature: (ion channel [6]; or ion exchanger [9, 11]). Structural data have revealed that ion channels form aqueous pores across the plasma membrane, whereas exchangers can have either large aqueous vestibules reaching deep into the bilayer of the membrane or form hourglass-like funnels with a narrow, and possibly water-excluding selectivity filter [17]. Channels and exchangers can be defined and distinguished by biophysical characteristics, such as ion flux rates (slower in exchangers), temperature-sensitivity (more so in exchangers) and dependence on both membrane voltage and concentration gradients of the transported ion species.

Several reports have presented experimental data suggesting that A1, A2 and A3 represent  $\text{Mg}^{2+}$  transport proteins [6, 7, 8, 9, 10, 11, 14]. A1 and A2 were originally considered to be putative  $\text{Mg}^{2+}$  transporters based on distant sequence homologies with the prokaryotic  $\text{Mg}^{2+}$  transporter MgtE [5]. Their initial functional characterizations used complementary RNA (cRNA) expression in *Xenopus* oocytes and membrane current recordings with two-electrode voltage-clamp (TEV) [6, 7, 8]. As the original A3 data were presented within a review article [8], only limited information is available about buffers composition and experimental procedures. Therefore, these will not be further discussed. Currents were compared between oocytes injected with  $\text{H}_2\text{O}$  and oocytes injected with A1 or A2 cRNA. The membrane potential was held at  $-15$  mV and currents were elicited with voltage steps of 2 s duration and ranging from  $-150$  mV to  $+25$  mV. Increasing extracellular  $\text{Mg}^{2+}$  concentrations from 0.2 mM to 10 mM gave rise to a saturable inward current at hyperpolarized potentials with an assessed reversal potential of about  $-20$  mV. Outward currents also seemed to increase in parallel, although this was less clear because of the absence of recordings above  $+25$  mV. Importantly, when using extracellular divalents other than  $\text{Mg}^{2+}$ , the oocyte experiments delineated a decrease in inward currents, with  $\text{Ca}^{2+}$  being particularly ineffective in eliciting any measurable currents. A1 and A2 were concluded to represent an  $\text{Mg}^{2+}$  transport mechanism with channel-like properties [6, 7], as the presented data could accommodate both, a constitutively active ion channel or an electrogenic ion exchange mechanism. Unfortunately, kinetic current data that could have

shed light on this issue were not provided in these publications [6, 7] and hence no definitive conclusion can be reached.

One way to differentiate between an ion channel and ion exchanger mechanism is to exploit the mandatory presence of both substrates for ion exchange to occur. Ion channels do not have this prerequisite as long as the permeating ion is available in sufficient quantities to move down its concentration gradient. The study of A1 by using *Xenopus* oocyte TEV tested for the possibility that A1 could be NME by removing  $\text{Na}^+$  from the extracellular solution [6]. This experimental manipulation did not alter the measured inward currents and thus favoured the concept of a constitutively active ion channel mechanism, if one assumed that the inward currents were indeed carried by A1. However, one of the major limitations of the TEV *Xenopus* oocyte system is the inability to control experimentally the internal milieu of the oocyte. Thus, any exogenously introduced protein could potentially activate unrelated endogenous currents such as swelling-and/or  $\text{Ca}^{2+}$ -activated chloride ( $\text{Cl}^-$ ) currents. As is well known, oocytes injected with  $\text{Ca}^{2+}$ , and to some extent with other divalent ions, induce  $\text{Cl}^-$  currents [18, 19, 20] and the expression of A1 or A2 might lead to such activation. In this context, it should be mentioned that the overexpression of A1 in HEK293 cells leads to the secondary activation of endogenous ATP-sensitive  $\text{Cl}^-$  currents [9]. The removal of external  $\text{Cl}^-$  from the solution, as mentioned in the experimental approach for A1 [6] does not help clarify whether the measured inward currents are carried by divalent ions or  $\text{Cl}^-$  ions, as  $\text{Cl}^-$  is a negatively charged ion and inward currents would reflect  $\text{Cl}^-$  efflux. For the same reason, the experiments in which  $\text{Na}^+$  was removed also remain open to this alternative explanation.

The first, and so far only, attempts at measuring A1 or A2 related whole-cell currents by using the patch-clamp technique were performed in tetracycline-inducible cell systems [9, 10, 14]. Whereas no obvious currents could be seen in A2-expressing DT40 chicken B cells [10], overexpression of A1 in HEK293 cells caused a secondary activation of an endogenous ATP-sensitive  $\text{Cl}^-$  current that was completely inhibited by the  $\text{Cl}^-$  channel blocker DIDS [9]. The latter experimental manipulation did not uncover any additional currents. Regardless, A1 or A2 expression clearly enables  $\text{Mg}^{2+}$  transport, as supercharging extracellular  $\text{Mg}^{2+}$  levels to 10 mM leads to an obvious increase in intracellular  $\text{Mg}^{2+}$  concentrations [9, 10, 14] and  $\text{Mg}^{2+}$ -transporter-deficient bacteria (*Salmonella sp.*) survive a  $\text{Mg}^{2+}$ -deprived environment when overexpressing A1 [9]. The greatest challenge of the ion channel hypothesis relates to the gating of the protein. If one takes the data acquired by TEV in the oocyte system at face value and if the measured currents are carried by A1/A2, one would have to consider SLC41 proteins as being constitutively active ion channels, since removal of external  $\text{Na}^+$  had no apparent effect on the currents and would therefore seem to exclude an electrogenic exchange mechanism [6, 7]. However, experiments performed using whole-cell patch-clamp conditions do not give rise to any measurable currents [9, 10], indicating that the SLC41 proteins are not constitutively active ion channels. Instead they might represent an ion channel mechanism whose gating mechanism awaits discovery or they are carriers that produce electroneutral ion exchange and remain undetectable electrophysiologically.

The most straightforward evidence implicating A1 as a  $\text{Mg}^{2+}$  transporter has emerged from functional complementation experiments in  $\text{Mg}^{2+}$ -transport-deficient *Salmonella sp.* strain MM281 transformed with pUC18-hSLC41A1 [9]. Here, an increase in extracellular  $\text{Mg}^{2+}$  concentrations to 10 mM significantly enhances intracellular  $\text{Mg}^{2+}$  concentrations. Given an experimental  $\text{Na}^+$  concentration of 0.5 mM  $[\text{Na}^+]_e$ , with an estimated 3 mM  $[\text{Na}^+]_i$  [9, 21], the driving ion in this situation is most likely to be  $\text{Mg}^{2+}$  with a concentration ratio of ~20 compared with a ratio of ~6 for  $\text{Na}^+$ . This allows  $\text{Mg}^{2+}$  flux into the bacteria, as these typically have highly negative membrane potentials when metabolically active [22]. The

very negative membrane potential also helps to explain the partial rescue of *Salmonella* growth in only 100  $\mu\text{M}$  extracellular  $\text{Mg}^{2+}$ . Under these experimental conditions both  $\text{Mg}^{2+}$  and  $\text{Na}^+$  have similar concentration ratios (8 and 6, respectively) and with a theoretical reversal potential of NME around  $-26$  mV under these conditions, the exchanger could potentially work in reverse mode, allowing  $\text{Mg}^{2+}$  influx and the efflux of  $\text{Na}^+$ .

The situation in mammalian cells, particularly in electrically non-excitable cells, is more complicated. Here,  $\text{Na}^+$  is the relevant driving ion for  $\text{Na}^+/\text{Mg}^{2+}$  exchange, as the ratio of its concentration across the membrane is at least 6-fold larger than that for  $\text{Mg}^{2+}$  ( $0.5$  mM  $[\text{Mg}^{2+}]_i/1$  mM  $[\text{Mg}^{2+}]_e$  versus  $12$  mM  $[\text{Na}^+]_i/145$  mM  $[\text{Na}^+]_e$ ). Since the direction of ion transport is defined by the equilibrium potential of the transported ions, A1 would normally extrude  $\text{Mg}^{2+}$  and import  $\text{Na}^+$  and reverse only when concentration gradients are experimentally manipulated to define artificially the driving ion species. This makes experiments with intact cells difficult to interpret, as the intracellular milieu is not easily manipulated, and alterations of extracellular ion conditions need to consider resulting changes in the transporter's reversal potential, the direction of transport, the relationship between driven and driving ion species and even the ability to transport ions. Considering that resting HEK293 cells may have a membrane potential of around  $-15$  mV [23], a resting  $\text{Mg}^{2+}$  concentration of  $0.2$  mM [9, 11] and that the external  $\text{Na}^+$  is usually high ( $145$  mM), at the physiological level of  $1$  mM external  $\text{Mg}^{2+}$ ,  $\text{Na}^+$  will be the driving ion. The relatively positive reversal potential ( $\sim +40$  mV) for NME that can be assumed under these conditions would favour constant  $\text{Mg}^{2+}$  extrusion. Indeed,  $\text{Mg}^{2+}$  extrusion plays a critical role in transcellular  $\text{Mg}^{2+}$  transport as seen during  $\text{Mg}^{2+}$  reabsorption in the distal convoluted tubule of the kidney [24]. This basolateral efflux of  $\text{Mg}^{2+}$  is thought to be  $\text{Na}^+$ -dependent [25].

Experimentally increasing external  $\text{Mg}^{2+}$  to high concentrations such as  $10$  mM would result in a shift of the driving ion from  $\text{Na}^+$  to  $\text{Mg}^{2+}$ , which now would have an estimated concentration ratio of  $50$  ( $10$  mM/ $0.2$  mM), thus driving  $\text{Mg}^{2+}$  influx and transporting  $\text{Na}^+$  against its concentration gradient. This indeed has been observed in HEK293 cells with or without overexpression of SLC41A1, whereby the presence of SLC41A1 has an amplifying effect on  $\text{Mg}^{2+}$  influx [11]. Furthermore, high external  $\text{Mg}^{2+}$  concentrations ( $15$  mM) rescue cell growth and proliferation of TRPM7-deficient DT40 chicken B cells overexpressing A1 [14] or A2 [10]. The removal of external  $\text{Mg}^{2+}$  while maintaining  $\text{Na}^+$  levels should also make  $\text{Mg}^{2+}$  the driving ion species for the exchanger, resulting in  $\text{Mg}^{2+}$  efflux at more positive potentials. Furthermore, this process should be inhibited by simply removing the external  $\text{Na}^+$ , and this is indeed observed in HEK293 cells overexpressing A1 [11].

### SLC41A1 as a $\text{Na}^+/\text{Mg}^{2+}$ exchanger

The basal  $[\text{Mg}^{2+}]_i$  of most cells is maintained between  $0.5$  to  $1.2$  mM and measurable  $\text{Mg}^{2+}$  transport has long been known to take place only when it is decreased or increased, e.g. by extracellular  $\text{Mg}^{2+}$  deficiency or after hormonal stimulation. Thus, to overcome this problem for  $\text{Mg}^{2+}$  transport studies, various methods such as  $\text{Mg}^{2+}$  depletion by incubation in  $\text{Mg}^{2+}$ -free media and artificial  $\text{Mg}^{2+}$  loading or the application of metabolic inhibitors [26, 27] must be used to generate conditions favouring the uptake or efflux of the ion.

Because the first functional data concerning A1-related transport [6] suggested a higher influx capacity in A1-overexpressing cells, Kolisek and colleagues [9] designed their experiments to promote  $\text{Mg}^{2+}$  uptake. Cells were  $\text{Mg}^{2+}$ -depleted by incubation in totally  $\text{Mg}^{2+}$ -free media and most experiments were performed under inwardly directed  $\text{Mg}^{2+}$  gradients ( $[\text{Mg}^{2+}]_i \ll [\text{Mg}^{2+}]_e$ ;  $2$ ,  $5$ , or  $10$  mM). This led to an  $[\text{Mg}^{2+}]_i$  increase composed of an A1-independent linear component (most probably channel-mediated) and an A1-

related temperature-sensitive component. The latter was insensitive to cobalt(III)hexaammine, a known inhibitor of bacterial/mitochondrial [28, 29] and mammalian [9]  $Mg^{2+}$  channels. Most interestingly, A1-overexpressing HEK293 cells, although  $Mg^{2+}$ -deficient showed a significant loss of  $Mg^{2+}$  when incubated under  $Mg^{2+}$ -free conditions ( $[Mg^{2+}]_i > [Mg^{2+}]_e$ : 0 mM). Measurements of the total [Mg] via AAS (atomic absorption spectroscopy) confirmed net  $Mg^{2+}$  transport showing a 12.7% increase and 25.6% loss of total [Mg] after a 20-min incubation in medium containing 5 mM or zero  $Mg^{2+}$ , respectively. Together, these results characterize A1 as a functional  $Mg^{2+}$  carrier and give the first evidence for the ability of the protein to mediate the efflux of the ion.

Kolisek and colleagues [11] have recently performed a second study with A1-overexpressing HEK293 cells to test whether the protein represents the molecular correlate of one of the postulated  $Mg^{2+}$  efflux systems. As any efflux activity is dependent on the  $[Mg^{2+}]_i$  [30], experiments were carried out with HEK293 cells that had been  $Mg^{2+}$ -loaded by a 20-min incubation in a 10 mM  $Mg^{2+}$ -containing medium. The A1-related  $Mg^{2+}$  extrusion was not directly linked to anion ( $Cl^-$ ,  $HCO_3^-$ ) transport. However, it showed typical features of NME such as 1) activation by an increased  $[Mg^{2+}]_i$  [26], 2) strict dependence on extracellular  $Na^+$  [31, 32], 3) inhibition by imipramine and quinidine [33] and, 4) regulation via cAMP-dependent PKA [33]. Thus, unquestionably, A1 represents NME, the predominant  $Mg^{2+}$  efflux system in mammalian cells [32, 34].

As known for other  $Na^+$ -dependent exchangers (e.g.  $Na^+/Ca^{2+}$  antiport,  $Na^+/H^+$  exchanger), the driving force for A1-mediated  $Na^+/Mg^{2+}$  exchange is, in the first instance, the inwardly directed concentration gradient for  $Na^+$  [11]. This makes the transporter directly dependent on extracellular  $Na^+$  and indirectly dependent on the  $Na^+/K^+$ -pump and thereby on ATP [11]. In comparison with controls, A1-overexpressing HEK293 cells have a high  $[Na^+]_i$  (about 40 mM) but reduced  $[Mg^{2+}]_i$  (about 0.1 mM). Therefore, increasing the extracellular  $Mg^{2+}$  concentration will reduce the driving force for an electroneutral  $Mg^{2+}$  efflux and makes it possible that the exchanger switches to the reverse mode, thereby performing  $Mg^{2+}$  uptake. This mode of operation has been shown in erythrocytes, heart muscle cells and rumen epithelium cells [35, 36, 37, 38] and might explain difficulties in identifying the natural function of A1 in some studies [14].

In general, for a correct interpretation of the results of functional studies, consideration of the functions of cells and/or tissues is essential. For example, in view of the function of NME for  $Mg^{2+}$  transport across the basolateral membrane of intestinal, renal and placental epithelia [39, 40], its transcription upregulation in specific cell types, e.g. renal distal tubule cells exposed to low Mg [8], is not surprising.  $Mg^{2+}$  influx systems such as TRPM6/TRPM7 or MagT1 are rapidly inactivated at normal  $Mg^{2+}$  concentrations. Thus an increased expression/activity of A1 could be interpreted as a mechanism to maintain a driving force for  $Mg^{2+}$  uptake under Mg-deficient conditions [41]. For this, only local changes of  $[Mg^{2+}]_i$  are sufficient; these can also be induced by the hormonal activation of A1 [42].

## SLC41 family and its involvement in human diseases

Systemic and intracellular magnesium insufficiency has long been suspected to contribute to the development and progress of cardiovascular, metabolic, neurological (neurodegenerative) and psychiatric diseases and also conditions associated with pregnancy such as preeclampsia and eclampsia [43, 44]. Several reports have recently been published linking A1 (as a key component of cellular and perhaps also of systemic  $Mg^{2+}$  homeostasis) with serious human illnesses.

Among the most exciting findings has been the discovery that A1 is part of a novel Parkinson's disease (PD) susceptibility locus *PARK16*. In this regard, Tucci and colleagues [45] identified a rare coding variant of A1 p.A350V putatively linked to PD. This study was shortly followed by a report of Yan and colleagues [46] identifying additional genetic variants of A1 present in a Chinese PD cohort, namely p.L146G, p.P480P and c.552 + 50G > A. Interestingly, a conditional knockout mouse line, designated as *Slc41a3<sup>tm1a(KOMP)Wtsi</sup>* (<http://www.knockoutmouse.org/martsearch/search?query=Slc41a3>), which was generated as part of the International Knockout Mouse Consortium program, displays abnormal locomotor coordination (<http://en.wikipedia.org/wiki/SLC41A3>).

Kolisek and colleagues [44] have performed an analysis of the transcription activities of magnesium-responsive genes in human placenta samples from the Mexican Mestizo cohorts of normoevolutive women and preeclamptic women. They found *A1* to be the only magnesium responsive gene with deregulated expression in the placentas of preeclamptic woman, with *A1* being significantly overexpressed in approximately 55% of tested preeclamptic samples and in only 9.5% of normoevolutive samples [44]. These findings strongly suggest an important role of A1 in the pathophysiology of preeclampsia.

A recently identified variant of A1, c.698G>T, has been associated with the nephronophthisis-like phenotype (NPHP-LP) [47]. This mutation results in the skipping of exon 6 of A1, leading to an in-frame deletion of a transmembrane helix [47]. Hurd and colleagues [47] suggest that defects in the maintenance of renal Mg<sup>2+</sup> homeostasis caused by mutated A1 lead to tubular defects that result in NPHP-LP.

## Conclusion

At the molecular and physiological level A1 is the best characterized protein out of the three members of the SLC41 family. From the experimental evidences it is obvious that A1 is an NME, a primary Mg<sup>2+</sup>-efflux system (able to operate also in a reverse mode under specific physiological conditions), and not a cation (Mg<sup>2+</sup>) channel as was assumed in the pilot report of Goytain and Quamme [6]. Little is known about the function of A2 and A3 in the context of intracellular Mg<sup>2+</sup> homeostasis or about the exact mode of their operation. However, based on the homology between A1 and the two other members of SLC41 family it could be assumed, that both A2 and A3 also function as Mg<sup>2+</sup> (X<sup>+</sup>) carriers.

Cellular localization and membrane topology of A2 and A3 also awaits further examination. Consensus is lacking on the orientation of the C-terminus of A1.

Nothing is known about complex-forming abilities of A2 and A3. A1 has been demonstrated to form transient heterooligomeric complexes with proteins probably being involved in its posttranslational maturation (modification), proper folding, anterograde transport and vesicular sorting. The interactions of A1 and its binding partners identified with the split-ubiquitin yeast two-hybrid assay await further examination.

Phosphorylation plays an important role in the regulation of A1 Na<sup>+</sup>/Mg<sup>2+</sup> exchange activity. The stimulating effect of cAMP-dependent PKA on A1 was already demonstrated. The effects of other protein kinases, which have been computer-predicted to phosphorylate A1, remain to be examined experimentally. Moreover, the predicted N-glycosylation and ubiquitination of A1 need further exploration.

No link has been established between A2 or A3 and any known disease. However, A1 has been identified to be a part of the PD susceptibility locus *PARK16* and its genetic variants exclusively associated with PD have been identified, predominantly in Asian (Chinese) cohorts. Moreover, recently, a link between preeclampsia and elevated expression of *A1* in



placental tissues has been demonstrated. The *A1* null mutation c.698G>T has been associated with the nephronophthisis-like phenotype. Further research will be needed to elucidate the exact role of *A1* (or its variants) in the pathophysiology of these diseases. Disturbed  $\text{Na}^+/\text{Mg}^{2+}$  exchange has been associated with cardiovascular and metabolic diseases. Therefore, any linkage of *A1* with such ailments in the future will be unsurprising. The wide spectrum of diseases involving *A1* (or  $\text{Na}^+/\text{Mg}^{2+}$  exchange) might also indicate an important role of *A1* in regulation of systemic Mg homeostasis.

## Acknowledgments


Our gratitude is due to Dr. Theresa Jones for linguistic corrections. This work was supported by the research grant from the German Research Foundation (DFG) KO-3586/3-2 to MK and by NIH Grant P01 GM078195 to AF. MSR and MK are inventors on the pending patent EP2011/065979 “ $\text{Na}^+/\text{Mg}^{2+}$  exchanger”.

## References


1. Park MH, Wong BB, Lusk JE. Mutants in three genes affecting transport of magnesium in *Escherichia coli*: genetics and physiology. *Journal of Bacteriology*. 1976; 126(3):1096–103. [PubMed: 780341]
2. Hmiel SP, Snavely MD, Miller CG, Maguire ME. Magnesium transport in *Salmonella typhimurium*: characterization of magnesium influx and cloning of a transport gene. *Journal of Bacteriology*. 1986; 168(3):1444–50. [PubMed: 3536881]
3. Hmiel SP, Snavely MD, Florer JB, Maguire ME, Miller CG. Magnesium transport in *Salmonella typhimurium*: genetic characterization and cloning of three magnesium transport loci. *Journal of Bacteriology*. 1989; 171(9):4742–51. [PubMed: 2548998]
4. Townsend DE, Esenwine AJ, George J 3rd, Bross D, Maguire ME, Smith RL. Cloning of the *mgtE*  $\text{Mg}^{2+}$  transporter from *Providencia stuartii* and the distribution of *mgtE* in gram-negative and gram-positive bacteria. *Journal of Bacteriology*. 1995; 177(18):5350–4. [PubMed: 7665526]
5. Wabakken T, Rian E, Kveine M, Aasheim HC. (2003) The human solute carrier SLC41A1 belongs to a novel eukaryotic subfamily with homology to prokaryotic *MgtE*  $\text{Mg}^{2+}$  transporters. *Biochemical and Biophysical Research Communications*. 2003; 306:718–24. [PubMed: 12810078]
6. Goytain A, Quamme GA. Functional characterization of human SLC41A1, a  $\text{Mg}^{2+}$  transporter with similarity to prokaryotic *MgtE*  $\text{Mg}^{2+}$  transporters. *Physiological Genomics*. 2005; 21(3):337–42. [PubMed: 15713785]
7. Goytain A, Quamme GA. Functional characterization of the mouse solute carrier, SLC41A2. *Biochemical and Biophysical Research Communications*. 2005; 330(3):701–5. Erratum in: *Biochemical and Biophysical Research Communications* 2007, 356(3), 822. [PubMed: 15809054]
8. Quamme GA. Molecular identification of ancient and modern mammalian magnesium transporters. *American Journal of Physiology Cell Physiology*. 2010; 298(3):C407–29. [PubMed: 19940067]
9. Kolisek M, Launay P, Beck A, Sponder G, Serafini N, Brenkus M, Froschauer EM, Martens H, Fleig A, Schweigel M. SLC41A1 is a novel mammalian  $\text{Mg}^{2+}$  carrier. *The Journal of Biological Chemistry*. 2008; 283:16235–16247. [PubMed: 18367447]
10. Sahni J, Nelson B, Scharenberg AM. SLC41A2 encodes a plasma-membrane  $\text{Mg}^{2+}$  transporter. *Biochemical Journal*. 2007; 401:505–513. [PubMed: 16984228]
11. Kolisek M, Nestler A, Vormann J, Schweigel-Rontgen M. Human gene SLC41A1 encodes for the  $\text{Na}^+/\text{Mg}^{2+}$  exchanger. *American Journal of Physiology Cell Physiology*. 2012; 302:C318–326. [PubMed: 22031603]
12. Romanuik TL, Wang G, Holt RA, Jones SJ, Marra MA, Sadar MD. Identification of novel androgen-responsive genes by sequencing of LongSAGE libraries. *BMC Genomics*. 2009; 10:476. [PubMed: 19832994]
13. Sahni J, Scharenberg AM. The SLC41 family of *MgtE*-like magnesium transporters. *Molecular Aspects of Medicine*. 2013; 34(2–3):620–8. [PubMed: 23506895]

14. Mandt T, Song Y, Scharenberg AM, Sahni J. SLC41A1  $Mg^{2+}$  transport is regulated via  $Mg^{2+}$ -dependent endosomal recycling through its N-terminal cytoplasmic domain. *Biochemical Journal*. 2011; 439(1):129–39. [PubMed: 21696366]
15. Sponder G, Rutschmann K, Kolisek M. Split-ubiquitin functional assay supports ten transmembrane “inside-in” topology of  $Na^+/Mg^{2+}$  exchanger SLC41A1. Submitted.
16. Nestler A, Sponder S, Rutschmann K, Mastrototaro L, Weise C, Vormann J, Schweigel-Röntgen M, Kolisek M. Nature of SLC41A1 complexes: report on split-ubiquitin yeast two hybrid assay. *Magnesium Research*. 2013; 26(2):56–66.10.1684/mrh.2013.0339 [PubMed: 23823179]
17. Gouaux E, Mackinnon R. Principles of selective ion transport in channels and pumps. *Science*. 2005; 310:1461–1465. [PubMed: 16322449]
18. Barish ME. A transient calcium-dependent chloride current in the immature *Xenopus* oocyte. *The Journal of Physiology*. 1983; 342:309–325. [PubMed: 6313909]
19. Miledi R, Parker I. Chloride current induced by injection of calcium into *Xenopus* oocytes. *The Journal of Physiology*. 1984; 357:173–183. [PubMed: 6096530]
20. Dascal N. Voltage clamp recordings from *Xenopus* oocytes. *Current Protocols in Neuroscience*. 2001; Chapter 6(Unit 6):12. [PubMed: 18428511]
21. Lo CJ, Leake MC, Berry RM. Fluorescence measurement of intracellular sodium concentration in single *Escherichia coli* cells. *Biophysical Journal*. 2006; 90:357–365. [PubMed: 16227503]
22. Shapiro HM. Membrane potential estimation by flow cytometry. *Methods*. 2000; 21:271–279. [PubMed: 10873481]
23. Sogaard R, Ljungstrom T, Pedersen KA, Olesen SP, Jensen BS. KCNQ4 channels expressed in mammalian cells: functional characteristics and pharmacology. *American Journal of Physiology Cell Physiology*. 2001; 280:C859–866. [PubMed: 11245603]
24. Alexander RT, Hoenderop JG, Bindels RJ. Molecular determinants of magnesium homeostasis: insights from human disease. *Journal of the American Society of Nephrology*. 2008; 19:1451–1458. [PubMed: 18562569]
25. Gunther T. Mechanisms and regulation of  $Mg^{2+}$  efflux and  $Mg^{2+}$  influx. *Mineral and Electrolyte Metabolism*. 1993; 19:259–265. [PubMed: 8264512]
26. Kubota T, Tokuno K, Nakagawa J, Kitamura Y, Ogawa H, Suzuki Y, Suzuki K, Oka K.  $Na^+/Mg^{2+}$  transporter acts as a  $Mg^{2+}$  buffering mechanism in PC12 cells. *Biochemical and Biophysical Research Communications*. 2003; 303(1):332–6. [PubMed: 12646207]
27. Flatman PW, Smith LM. Magnesium transport in magnesium-loaded ferret red blood cells. *Pflugers Archive*. 1996; 432(6):995–1002. [PubMed: 8781193]
28. Kolisek M, Zsurka G, Samaj J, Weghuber J, Schweyen RJ, Schweigel M. Mrs2p is an essential component of the major electrophoretic  $Mg^{2+}$  influx system in mitochondria. *EMBO Journal*. 2003; 22(6):1235–44. [PubMed: 12628916]
29. Kucharski LM, Lubbe WJ, Maguire ME. Cation hexaamines are selective and potent inhibitors of the CorA magnesium transport system. *Journal of Biological Chemistry*. 22(22):16767–73.10.1074/jbc.M001507200
30. Büttner S, Günther T, Schäfer A, Vormann J. Magnesium metabolism in erythrocytes of various species. *Magnesium-Bulletin*. 1998; 20:101–9.
31. Yoshimura M, Oshima T, Matsuura H, Watanabe M, Higashi Y, Ono N, Hiraga H, Kambe M, Kajiyama G. Effect of the transmembrane gradient of magnesium and sodium on the regulation of cytosolic free magnesium concentration in human platelets. *Clinical Science (London)*. 1995; 89(3):293–8.
32. Schweigel M, Park HS, Etschmann B, Martens H. Characterization of the  $Na^+$ -dependent  $Mg^{2+}$  transport in sheep ruminal epithelial cells. *American Journal of Physiology Gastrointestinal and Liver Physiology*. 2006; 290(1):G56–65. [PubMed: 16109844]
33. Schweigel M, Kuzinski J, Deiner C, Kolisek M. Rumen epithelial cells adapt magnesium transport to high and low extracellular magnesium conditions. *Magnesium Research*. 2009; 22(3):133–50. [PubMed: 19780400]
34. Fagan TE, Romani A.  $\alpha(1)$ -Adrenoceptor-induced  $Mg^{2+}$  extrusion from rat hepatocytes occurs via  $Na^+$ -dependent transport mechanism. *American Journal of Physiology Gastrointestinal and Liver Physiology*. 2001; 280(6):G1145–56. [PubMed: 11352807]

35. Schweigel M, Vormann J, Martens H. Mechanisms of  $Mg^{2+}$  transport in cultured ruminal epithelial cells. *American Journal of Physiology Gastrointestinal and Liver Physiology*. 2000; 278(3):G400–8. [PubMed: 10712259]
36. Günther T, Vormann J. Reversibility of  $Na^+/Mg^{2+}$  antiport in rat erythrocytes. *Biochimica et Biophysica Acta*. 1995; 1234(1):105–10. [PubMed: 7880850]
37. Flatman PW, Smith LM. Sodium-dependent magnesium uptake by ferret red cells. *Journal of Physiology*. 1991; 443:217–30. [PubMed: 1822527]
38. Tashiro M, Tursun P, Konishi M. Intracellular and extracellular concentrations of  $Na^+$  modulate  $Mg^{2+}$  transport in rat ventricular myocytes. *Biophysical Journal*. 2005; 89(5):3235–47. [PubMed: 16085772]
39. Quamme GA. Control of magnesium transport in the thick ascending limb. *American Journal of Physiology*. 1989; 256(2 Pt 2):F197–210. [PubMed: 2644845]
40. Leonhard-Marek S, Stumpff F, Brinkmann I, Breves G, Martens H. Basolateral  $Mg^{2+}/Na^+$  exchange regulates apical nonselective cation channel in sheep rumen epithelium via cytosolic  $Mg^{2+}$ . *American Journal of Physiology Gastrointestinal and Liver Physiology*. 2005; 288(4):G630–45. [PubMed: 15550561]
41. He Y, Yao G, Savoia C, Touyz RM. Transient receptor potential melastatin 7 ion channels regulate magnesium homeostasis in vascular smooth muscle cells: role of angiotensin II. *Circulation Research*. 2005; 96(2):207–15. [PubMed: 15591230]
42. Fatholati M, LaNoue K, Romani A, Scarpa A. Relationship between total and free cellular  $Mg^{2+}$  during metabolic stimulation of rat cardiac myocytes and perfused hearts. *Archives of Biochemistry and Biophysics*. 2000; 374:395–401. [PubMed: 10666323]
43. Nishizawa, Y.; Morii, H.; Durlach, J. *New Perspectives in Magnesium Research (Nutrition and Health)*. Springer-Verlag London Ltd; 2007.
44. Kolisek M, Galaviz-Hernández C, Vázquez-Alaniz F, Sponder G, Javaid S, Kurth K, Nestler A, Rodríguez-Moran M, Verlohren S, Guerrero-Romer F, Aschenbach JR, Vormann J. *SLC41A1* is the only magnesium responsive gene significantly overexpressed in placentas of preeclamptic women. *Hypertension in Pregnancy*. 2013 Ahead of print.
45. Tucci A, Nalls MA, Houlden H, Revesz T, Singleton AB, Wood NW, Hardy J, Paisán-Ruiz C. Genetic variability at the PARK16 locus. *European Journal of Human Genetics*. 2010; 18(12): 1356–9. 10.1038/ejhg.2010.125 [PubMed: 20683486]
46. Yan Y, Tian J, Mo X, Zhao G, Yin X, Pu J, Zhang B. Genetic variants in the RAB7L1 and SLC41A1 genes of the PARK16 locus in Chinese Parkinson's disease patients. *International Journal of Neuroscience*. 2011; 121(11):632–6. 10.3109/00207454.2011.598983 [PubMed: 21812739]
47. Hurd TW, Otto EA, Mishima E, Gee HY, Inoue H, Inazu M, Yamada H, Halbritter J, Seki G, Konishi M, Zhou W, Yamane T, Murakami S, Caridi G, Ghiggeri G, Abe T, Hildebrandt F. Mutation of the  $Mg^{2+}$  Transporter SLC41A1 Results in a Nephronophthisis-Like Phenotype. *Journal of the American Society of Nephrology*. 2013 Ahead of print.



**Figure 1.** Models of membrane topology of SLC41A1 (A) and SLC41A2 (B) constructed according to available peer-reviewed bibliography. Plot C depicts a computer predicted-model (TMPRED) of SLC41A3 topology.



**Figure 2.**

SLC41A1, networks depicting cellular localization (A) and function (B) of its interactors.

(A) CM = cytoplasmic membrane, M(NS) = membranes (non-specified), MI = mitochondria, ER = endoplasmic reticulum, GA = Golgi apparatus, NU = nucleus, CY = cytoplasm; (B) APO-reg = apoptosis (regulation), PNG = proteoneogenesis, PF = protein folding, PM = protein maturation, N-Gly = N-glykosylation, Ub = ubiquitination, S = secretion, AT = anterograde transport, SLC-ER = solute transport in endoplasmic reticulum and Golgi, CHM = cholesterol metabolism (biosynthesis), LM = lipids metabolism (biosynthesis).

Table 1

Mg <sup>2+</sup> transporter	Gene	Function	Localization	Reference
SLC41A1	NU	Na <sup>+</sup> /Mg <sup>2+</sup> exchanger (primarily Mg <sup>2+</sup> efflux system)	CM	[5, 9, 11, 47]
SLC41A2	NU	putative Mg <sup>2+</sup> carrier Mg <sup>2+</sup> transport mechanism with channel like properties	CM?, IMC?	[7, 10, 13]
SLC41A3	NU	putative Mg <sup>2+</sup> carrier Mg <sup>2+</sup> transport mechanism with channel like properties	CM? IMC?	[8]
NIPA1	NU	Mg <sup>2+</sup> transport mechanism with channel like properties	CM	[ <i>a</i> ]
NIPA2	NU	Mg <sup>2+</sup> transport mechanism with channel like properties	CM	[ <i>b</i> ]
MagT1	NU	putative Mg <sup>2+</sup> channel	CM	[ <i>c</i> ]
N33/TUSC3	NU	putative function in cellular Mg <sup>2+</sup> - homeostasis	CM	[ <i>c</i> ]
TRPM6	NU	chanzyme/cation channel	CM	[ <i>d</i> ]
TRPM7	NU	chanzyme/cation channel	CM	[ <i>e</i> ]
MRS2	NU	Mg <sup>2+</sup> channel	IMM	[28]
HIP14	NU	Mg <sup>2+</sup> transport mechanism with chanzyme like properties	GA,	[ <i>f</i> ]
HIP14L	NU	Mg <sup>2+</sup> transport mechanism with chanzyme like properties	GA,	[ <i>f</i> ]
MMgT1	NU	Mg <sup>2+</sup> transport mechanism putative carrier	GA, PGV	[ <i>g</i> ]
MMgT2	NU	Mg <sup>2+</sup> transport mechanism with putative carrier	GA, PGV	[ <i>g</i> ]
CNNM2/ACDP2	NU	putative Mg <sup>2+</sup> or cellular Mg <sup>2+</sup> homeostatic factor	CM, IMC, N	[ <i>h,i,j</i> ]

Abbreviations: NU = nuclear, CM = cytoplasmic membrane, IMC = intracellular membrane compartments, IMM = inner mitochondrial membrane, GA = Golgi apparatus, PGV = post-Golgi vesicles, ? = possible, putative.

References indicated with a number are included in the main references list. Following references are specific to this table and they were not used elsewhere:

<sup>a</sup>Goytain A, Hines RM, El-Husseini A, et al. NIPA1 (SPG6), the basis for autosomal dominant form of hereditary spastic paraplegia, encodes a functional Mg<sup>2+</sup> transporter. *Journal of Biological Chemistry* 2007, 282(11):8060–8;

<sup>b</sup>Goytain A, Hines RM, Quamme GA. Functional characterization of NIPA2, a selective Mg<sup>2+</sup> transporter. *American Journal of Physiology Cell Physiology* 2008, 295(4):C944–53;

<sup>c</sup>Zhou H, Clapham DE. Mammalian MagT1 and TUSC3 are required for cellular magnesium uptake and vertebrate embryonic development. *Proceedings of the National Academy of Sciences USA*. 2009, 106(37):15750–5;

<sup>d</sup>Schlingmann KP, Weber S, Peters M, et al. Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family. *Nature Genetics* 2002, 31(2):166–70;

<sup>e</sup>Runnels LW, Yue L, Clapham DE. TRP-PLIK, a bifunctional protein with kinase and ion channel activities. *Science* 2001, 291(5506):1043–7;

<sup>f</sup>Goytain A, Hines RM, Quamme GA. Huntingtin-interacting proteins, HIP14 and HIP14L, mediate dual functions, palmitoyl acyltransferase and Mg<sup>2+</sup> transport. *Journal of Biological Chemistry* 2008, 283(48):33365–74;

<sup>g</sup>Goytain A, Quamme GA. Identification and characterization of a novel family of membrane magnesium transporters, MMgT1 and MMgT2. *American Journal of Physiology Cell Physiology* 2008, 294(2):C495–502;

<sup>h</sup>Wang CY, Shi JD, Yang P, et al. Molecular cloning and characterization of a novel gene family of four ancient conserved domain proteins (ACDP). *Gene* 2003, 306:37–44;

<sup>i</sup>Sponder G, Svidova S, Schweigel M, et al. Splice-variant 1 of the ancient domain protein 2 (ACDP2) complements the magnesium-deficient growth phenotype of *Salmonella enterica* sv. typhimurium strain MM281. *Magnesium Research* 2010, 23(2):105–14;

<sup>j</sup>de Baaij JH, Stuiver M, Meij IC, et al. Membrane topology and intracellular processing of cyclin M2 (CNNM2). *Journal of Biological Chemistry* 2012, 287(17):13644–55.

**Table 2**

Predictions of SLC41A1 topology generated with various prediction software.

10 TM helices	TM1	TM2	TM3	TM4	TM5	TM6	TM7	TM8	TM9	TM10	C-	
	N-	i-o	o-i	i-o	o-i	i-o	o-i	i-o	o-i	i-o	o-i	C-
TMPred <sup>1</sup>	in	96 123	185 205	225 242	261 279	286 306	319 337	348 364	411 427	439 463	483 503	in
TopPred II <sup>2</sup>	in	100 120	185 205	222 242	259 279	286 306	318 338	344 364	411 431	435 455	486 506	in
PSORT II <sup>3</sup>	in	107 123	128 144	188 204	225 241	257 273	290 306	322 338	411 427	439 455	488 504	in
MEMSAT SVM <sup>4,5,6</sup>	in	98 121	135 150	181 202	214 241	258 277	286 306	315 338	407 431	436 466	481 502	in
TOP-CONS <sup>7</sup>	in	100 120	140 160	181 201	222 242	261 281	285 305	317 337	409 429	443 463	484 504	in
SCAMPI- seq <sup>8</sup>	in	102 122	129 149	185 205	222 242	261 281	285 305	317 337	407 427	437 457	484 504	in

10 TM helices	TM1	TM2	TM3	TM4	TM5	TM6	TM7	TM8	TM9	TM10	C-	
	N-	-	-	-	-	-	-	-	-	-	C-	
DAS c.off 2.2 <sup>9</sup>	-	100 115	136 143	189 201	221 241	264 273	289 304	325 332	411 425	437 460	489 502	-
Split 4.0/0	-	96 125	178 206	212 242	254 278	286 305	320 336	346 368	411 430	434 465	479 501	-

10 TM helices	TM1	TM2	TM3	TM4	TM5	TM6	TM7	TM8	TM9	TM10	C-	
	N-	o-i	i-o	o-i	i-o	o-i	o-i	i-o	o-i	i-o	C-	
TMHMM <sup>1</sup>	out	98 120	182 204	219 241	257 279	284 306	315 337	347 366	411 428	438 460	481 503	out

9 TM helices	TM1	TM2	TM3	TM4	TM5	TM6	TM7	TM8	TM9	C-	
	N-	o-i	i-o	o-i	i-o	o-i	o-i	i-o	o-i	o-i	C-
Predict Protein <sup>12</sup>	out	101 118	183 200	220 238	261 278	287 304	319 336	412 429	442 459	484 501	in
Phobius <sup>13</sup>	out	98 123	180 204	210 241	253 274	286 305	317 337	409 427	439 459	479 504	in
OCTO- PUS <sup>14</sup>	out	103 123	181 201	222 242	261 281	285 305	320 340	409 429	443 463	484 504	in



9 TM helices	TM1	TM2	TM3	TM4	TM5	TM6	TM7	TM8	TM9
	<b>o-i</b>	<b>i-o</b>	<b>o-i</b>	<b>i-o</b>	<b>o-i</b>	<b>i-o</b>	<b>o-i</b>	<b>i-o</b>	<b>o-i</b>
SCAMPI- <i>msa/5</i>	103 out	181 201	222 242	261 281	285 305	320 340	409 429	443 463	484 504
									<b>C-</b> in

8 TM helices	TM1	TM2	TM3	TM4	TM5	TM6	TM7	TM8	
	<b>o-i</b>	<b>i-o</b>	<b>o-i</b>	<b>i-o</b>	<b>o-i</b>	<b>i-o</b>	<b>o-i</b>	<b>i-o</b>	
MEMSAT3 <sup>5</sup>	100 121	179 203	217 241	251 274	286 309	409 432	443 467	478 500	
									<b>C-</b> out

11 TM helices	TM1	TM2	TM3	TM4	TM5	TM6	TM7	TM8	TM9	TM10	TM11
	<b>i-o</b>	<b>o-i</b>	<b>i-o</b>	<b>o-i</b>	<b>i-o</b>	<b>o-i</b>	<b>i-o</b>	<b>o-i</b>	<b>i-o</b>	<b>o-i</b>	<b>i-o</b>
HMMTOP 2.0 <sup>16</sup>	96 120	135 154	185 204	217 241	254 273	286 305	318 337	346 365	411 430	439 458	479 498
PRO <sup>17</sup>	100 120	141 161	182 202	223 243	253 273	285 305	315 335	346 366	409 429	440 460	481 501
PRO-DIV <sup>17</sup>	99 119	140 160	181 201	222 242	254 274	286 306	316 336	349 369	407 427	440 460	481 501
											<b>C-</b> out

11 TM helices	TM1	TM2	TM3	TM4	TM5	TM6	TM7	TM8	TM9	TM10	TM11
	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>C-</b>
SOSUI <sup>8</sup>	99 121	128 150	180 202	219 241	256 278	285 306	317 339	346 368	408 430	437 459	481 503
											<b>C-</b> -

The predictions were generated according respective algorithms described in:

- Hofmann K, Stoffel W. TMbase - A database of membrane spanning proteins segments. *Biol. Chem. Hoppe-Seyler*. 1993, 374:166;
- von Heijne G. Membrane Protein Structure Prediction, Hydrophobicity Analysis and the Positive-inside Rule. *J. Mol. Biol.* 1992, 225:487-94;
- Mitsuteru C, Nakao CM, Nakai K. Improvement of PSORT II Protein Sorting Prediction for Mammalian Proteins. *Genome Informatics*. 2002, 13:441-2;
- Nugent T, Jones DT. Transmembrane protein topology prediction using support vector machines. *BMC Bioinformatics*. 2009, 10:159;
- Jones DT. Improving the accuracy of transmembrane protein topology prediction using evolutionary information. *Bioinformatics*. 2007, 23:538-44;
- Jones DT, Taylor WR, Thornton JM. A Model Recognition Approach to the Prediction of All-Helical Membrane Protein Structure and Topology. *Biochem. Biophys. Res. Commun.* 1994, 33:3038-49;
- Bernsel A, Viklund H, Hennedal A, et al. TOPCONS: consensus prediction of membrane protein topology. *Nucleic Acids Res*. 2009, 37:W465-8;
- <http://scampi.cbr.su.se/index.php?about=SCAMPI>;
- Cserzo M, Wallin E, Simon I, et al. Prediction of transmembrane alpha-helices in prokaryotic membrane proteins: the Dense Alignment Surface method. *Prot. Eng.* 1997, 10(6):673-6;

- <sup>10</sup> Juretic D, Zoranic L, Zucic D. Basic charge clusters and predictions of membrane protein topology. *J. Chem. Inf. Comput. Sci.* 2002, 42:620–32;
- <sup>11</sup> Krogh A, Larsson B, von Heijne G, et al. Predicting Transmembrane Protein Topology with a Hidden Markov Model: Application to Complete Genomes. *J. Mol. Biol.* 2001, 305:567–80;
- <sup>12</sup> Rost B, Yachdav G, Liu J. The PredictProtein server. *Nucleic Acids Res.* 2004, 32:W321–26;
- <sup>13</sup> Kääll L, Krogh A, Sonnhammer ELL. A Combined Transmembrane Topology and Signal Peptide Prediction Method. *Journal of Molecular Biology*, 2004, 338(5):1027–36;
- <sup>14</sup> Viklund H, Elfösson A. A method that improves topology prediction for transmembrane proteins by using two-track ANN-based preference scores and an improved topological grammar. *Bioinformatics*, 2008, 24:1662–8;
- <sup>15</sup> <http://scampi.cbr.su.se/index.php?about=SCAMPI>;
- <sup>16</sup> Tusnády GE, Simon I. The HMMTOP transmembrane topology prediction server. *Bioinformatics*. 2001, 17:849–850;
- <sup>17</sup> <http://topcons.cbr.su.se/index.php?about=proprodv>;
- <sup>18</sup> Hirokawa T, Boon-Chiang S, Mitaku S, SOSUI: classification and secondary structure prediction system for membrane proteins. *Bioinformatics*. 1998; 14(4):378–9.